Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method of modulating a peptide specific T cell response, said method comprising contacting said T cell with an MHC-peptide complex, which peptide comprises at least one β-amino acid substitution, wherein said β-amino acid substitution induces either agonism or antagonism of said T cell response relative to the T cell response inducible by a non-substituted form of said peptide.

2. (Original) A method of modulating a peptide specific T cell response in a subject, said method comprising administering to said subject an effective amount of a peptide, which peptide comprises at least one β-amino acid substitution, for a time and under conditions sufficient to present said peptide to said T cell in the context of an MHC-peptide complex, wherein said β-amino acid substitution induces either agonism or antagonism of said T cell response relative to the T cell response inducible by a non-substituted form of said peptide.

3. (Currently Amended) The method according to claim 1 ~~or 2~~ wherein said T cell is a $CD8^+$ T cell and said MHC is MHC I.

4. (Original) The method according to claim 3 wherein said peptide comprises 2-50 amino acid residues.

5. (Original) The method according to claim 4 wherein said peptide comprises 2-40 amino acid residues.

6. (Original) The method according to claim 5 wherein said peptide comprises 2-30 amino acid residues.

7. (Original) The method according to claim 6 wherein said peptide comprises 2-20 amino acid residues.

8. (Original) The method according to claim 7 wherein said peptide comprises 2-15 amino acid residues.

9. (Currently Amended) The method according to any one of claims 1-~~8~~ wherein said response is T cell activation.

10. (Currently Amended) The method according to claim 9 wherein said activation is ~~agonised~~agonized.

11. (Currently Amended) The method according to claim 9 ~~or 10~~ wherein said peptide is a tumour derived peptide.

12. (Original) The method according to claim 11 wherein said tumour derived peptide is from NY-ESO, MUC1, MAGE, BAGE, RAGE or CAGE.

13. (Currently Amended) The method according to claim 9 ~~or 10~~ wherein said peptide is a virus derived peptide.

14. (Original) The method according to claim 13 wherein said virus is Epstein Barr Virus, Cytomegalovirus, human immunodeficiency virus or Hepatitis C virus.

15. (Currently Amended) The method according to claim 9 ~~or 10~~ wherein said peptide is a tolerogenic epitope.

16. (Original) The method according to claim 15 wherein said tolerogenic epitope is derived from Myelin Basic Protein (MBP).

17. (Currently Amended) The method according to ~~any one of~~ claims 1-~~16~~ wherein said amino acid substitutions are substitutions of said peptide's MHC anchor residues.

18. (Currently Amended) The method according to ~~any one of~~ claims 1-~~8~~ wherein said response is the induction of anergy or tolerance of pathological T cells.

19. (Currently Amended) The method according to ~~any one of~~ claims 1-~~8~~ wherein said response is the induction of a polyclonal T cell response.

20. (Currently Amended) A method of ~~agonising~~ agonizing a peptide specific T cell response in a subject, said method comprising co-administering to said subject an effective amount of an antagonistic peptide, which peptide comprises at least one β-amino acid substitution, together with the non-substituted form of said peptide for a time and under conditions sufficient to present said peptides to said T cells in the context.

21. (Currently Amended) A method of ~~antagonising~~ antagonizing a peptide specific T cell response in a subject, said method comprising co-administering to said subject an effective amount of an agonistic peptide, which peptide comprises at least one β-amino acid substitution, together with the non-substituted form of said peptide for a time and under conditions sufficient to present said peptides to said T cells in the context of an MHC-peptide complex.

22. (Currently Amended) A method for the treatment and/or prophylaxis of a condition ~~characterised~~characterized by an aberrant, unwanted or otherwise inappropriate peptide specific T cell response in a subject, said method comprising administering to said subject an effective amount of a peptide, which peptide comprises at least one β-amino acid substitution, for a time and under conditions sufficient to present said peptide to said T cell in the context of an MHC-peptide complex, wherein said β-amino acid substitution induces either agonism or antagonism of said T cell response relative to the T cell response inducible by a non-substituted form of said peptide.

23. (Original) The method according to claim 22 wherein said T cell is a $CD8^+$ T cell and said MHC is MHC I.

24. (Original) The method according to claim 23 wherein said peptide comprises 2-50 amino acid residues.

25. (Original) The method according to claim 24 wherein said peptide comprises 2-40 amino acid residues.

26. (Original) The method according to claim 25 wherein said peptide comprises 2-30 amino acid residues.

27. (Original) The method according to claim 26 wherein said peptide comprises 2-20 amino acid residues.

28. (Original) The method according to claim 27 wherein said peptide comprises 2-15 amino acid residues.

29. (Currently Amended) The method according to claim 22~~-28~~ wherein said response is T cell activation.

30. (Original) The method according to claim 29 wherein said activation is agonised.

31. (Currently Amended) The method according to claim 29~~-or 30~~ wherein said condition is a tumour and said peptide is a tumour derived peptide.

32. (Original) The method according to claim 31 wherein said tumour derived peptide is from NY-ESO, MUC1, MAGE, BAGE, RAGE or CAGE.

33. (Currently Amended) The method according to claim 29~~-or 30~~ wherein said condition is a viral infection and said peptide is a virus derived peptide.

34. (Original) The method according to claim 33 wherein said virus is EBV, CMV, HIV or CIV.

35. (Currently Amended) The method according to claim 29~~-or 30~~ wherein said condition is multiple sclerosis and said peptide is a tolerogenic peptide.

36. (Original) The method according to claim 35 wherein said tolerogenic epitope is MBP.

37. (Currently Amended) The method according to ~~any one of~~ claims 22~~-28~~ wherein said response is the induction of ~~amergy~~ anergy or tolerance of pathological T cells.

38. (Currently Amended) The method according to ~~any one of~~ claims 22~~-28~~ wherein said response is the induction of a polyclonal T cell response.

39. (Currently Amended) A method for the treatment and/or prophylaxis of a condition ~~characterised~~characterized by the occurrence of an unwanted peptide specific T cell response in a subject, said method comprising co-administering to said subject an effective amount of an agonistic peptide, which peptide comprises at least one β-amino acid substitution together with a non-substituted form of said peptide for a time and under conditions sufficient to present said peptides to said T cells in the context of an MHC peptide complex.

40. (Currently Amended) A method for the treatment and/or prophylaxis of a condition ~~characterised~~characterized by an inadequate peptide specific T cell response in a subject, said method comprising co-administering to said subject an effective amount of an antagonist peptide, which peptide comprises at least one β-amino acid substitution, together with a non-substituted form of said peptide for a time and under conditions sufficient to present said peptides to said T cells in the context of an MHC peptide complex.

41. (Original) The method according to claim 39 wherein said condition is an autoimmune condition, a transplant or an allergic condition.

42. (Original) The method according to claim 40 wherein said condition is a neoplastic condition or an infection.

43. (Canceled)

44. (Original) A pharmaceutical composition comprising a β-amino acid substituted peptide together with one or more pharmaceutically acceptable carriers and/or diluents.

45. (Original) A method of designing and screening for β-amino acid substituted peptide analogues, which method provides a means of rationally substituting α-amino acids for β-amino acids in a positional scanning approach and the identification of peptides exhibiting desired functional activity and improved bioavailability.